Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Novo Nordisk
Deal Size : $4,790.0 million
Deal Type : Expanded Collaboration
Valo, Novo Nordisk Expand Collaboration on Cardiometabolic Disease Therapies
Details : The expanded collaboration will continue to utilize Valo's Opal Computational Platform, while Novo remains actively engaged in multiple small molecule preclinical drug discovery programs.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Novo Nordisk
Deal Size : $4,790.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : OPL-0401
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valo Abandons Rock Inhibitor After Diabetic Retinopathy Fail
Details : OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1/2 inhibitor and a potential first-in-class oral option which is being evaluated for the treatment of diabetic retinopathy.
Product Name : OPL-0401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2025
Lead Product(s) : OPL-0401
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPL-0401
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Valo Health Completes Enrollment of OPL-0401 Phase 2 Study
Details : OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1/2 inhibitor and a potential first-in-class oral option which is being evaluated for diabetic retinopathy.
Product Name : OPL-0401
Product Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2024
Lead Product(s) : OPL-0401
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $2,760.0 million
Deal Type : Collaboration
Details : The collaboration will leverage Valo’s Opal Computational Platform including access to real-world patient data, AI-enabled small molecule discovery and Biowire® human tissue modelling platform to discover and develop novel treatments for cardiometabol...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $2,760.0 million
Deal Type : Collaboration
Lead Product(s) : OPL-0401
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1⁄2 inhibitor and a potential first-in-class oral option for patients with NPDR, where the current treatment options are intravitreal injections, surgery, or lase...
Product Name : OPL-0401
Product Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2022
Lead Product(s) : OPL-0401
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?